27 states and D.C. filed a lawsuit to block the sale of personal genetic data by 23andMe without customer consent as a biotech company seeks to buy the struggling firm in bankruptcy court.
Key Points
27 states and D.C. filed a lawsuit to prevent the sale of personal genetic data by 23andMe without customer consent
Regeneron Pharmaceuticals aims to buy 23andMe for $256 million and promises to comply with privacy policies and laws
Court-appointed privacy ombudsman to review the proposed sale's impact on consumer privacy
Pros
Protecting sensitive genetic data of individuals
Ensuring customer consent is required for the sale of personal information